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CommentaryProbiotic therapy - recruiting old friends to fight 
new foes
Roy D Sleator1,2
Abstract
Against a backdrop of increasing antibiotic resistance, and the emergence of new and evolving pathogens, clinicians 
are increasingly forced to consider alternative therapies - probiotics are one such alternative.
The problem
With life-cycles measured in minutes as opposed to
years, bacteria have an extraordinary ability to evolve and
adapt rapidly to changes in their environment [1]. Thus,
in a world where only the fittest survive, those bacteria
which have developed resistance to antibiotics will pre-
dominate. This is particularly apparent in hospital envi-
ronments where bacteria are in constant contact with
many different antibiotics; such repeated exposure has
facilitated the development of multiple antibiotic resis-
tance and the emergence of ever more virulent nosoco-
mial infections.
Probiotic Therapy - a possible solution?
Faced with an emerging pandemic of antibiotic resis-
tance, clinicians and scientists alike are now struggling to
find viable therapeutic alternatives to our failing antibi-
otic wonder drugs [2]. One such alternative may be bacte-
ria themselves - the application of probiotics; so called
"good bugs" (Fig. 1), for therapeutic effect [3,4]. While the
exact mechanisms by which probiotic bacteria inhibit
pathogens are as yet poorly understood, some advances
have nevertheless been made in our understanding of
probiotic function [5]. In addition to competing with
pathogens for niches and nutrients, "competitively
excluding" disease causing microbes from the host [6],
certain probiotic bacteria have also been shown to pro-
duce potent antimicrobial peptides (bacteriocins) which
specifically target the invading pathogen [7] (Fig. 2A).
While traditional antibiotics usually exert their activities
via a specific mode of action; for example, penicillin
interferes with the cross-linking of two linear polymers
by inhibiting the transpeptidase reaction, bacteriocins on
the other hand have quite diverse activities. Nisin and
many other structurally related lantibiotics for example,
use the cell wall precursor lipid II bound to the mem-
brane as a docking molecule for pore formation and com-
bine at least two modes of action, i.e., pore formation and
inhibition of cell wall biosynthesis, for antibacterial activ-
ity at nanomolar concentrations [8]. These multiple
modes of action significantly reduce (but do no eliminate)
the risk of resistance development [9].
However, despite their potent anti-pathogenic effect, a
significant limitation of this approach is that probiotic
bacteria tend to be physiologically fragile; often not sur-
viving to sufficiently high numbers during prolonged
storage in delivery matrices such as foods (yogurt and
probiotic drinks) or tablet formulations [10]. Further-
more, following ingestion, the already depleted probiotics
must face the considerable physiological defences of the
host (gastric acidity, bile, low iron, elevated osmolarity
and temperature) in order to colonize the gastrointestinal
tract in sufficient numbers to exert a therapeutic effect
[11,12].
Patho-biotechnology - making good bugs better
One approach to improving the physiological robustness
and stress tolerance of probiotic strains is patho-biotech-
nology [13,14]. Essentially, this novel approach involves
the generation of "improved" probiotic strains, using
stress survival systems mined from more physiologically
robust pathogenic microbes [15]. The physiological ver-
satility of pathogenic genera, oscillating between the
external environment and the host, makes them a verita-
ble treasure trove of genes that could potentially be used
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to improve the technological robustness of less well
adapted probiotic strains [16]. Indeed, recent work in our
laboratory has shown that cloning and heterologous
expression of a single bile resistance gene, from the food
borne pathogen Listeria monocytogenes in the probiotic
strain Bifidobacterium breve, not only improves gastroin-
testinal colonisation and persistence, but also signifi-
cantly bolsters the clinical efficacy of the probiotic strain
[17].
Therapy
In addition to improving their physiological stress toler-
ance, resulting in improved delivery and persistence
within the gut, recent studies have led to the development
of 'designer probiotics' which specifically target enteric
infections by blocking crucial ligand-receptor interac-
tions between the pathogen and its target host cell
[10,18,19]. Many disease causing bacteria exploit oligo-
saccharides displayed on the surface of host cells as
receptors for toxins and/or adhesions, enabling coloniza-
tion of the mucosa and entry of the pathogen or secreted
toxins into the host cell. Blocking this adherence prevents
infection (Fig. 2B), while toxin neutralization ameliorates
symptoms until the pathogen is eventually overcome by
the host immune system (Fig. 2C). 'Designer probiotics'
have been engineered to express receptor-mimic struc-
tures on their surface [20]. When administered orally
these probiotics bind to and neutralize toxins in the gut
lumen and interfere with pathogen adherence to the
intestinal epithelium - thus essentially "mopping up" the
infection. A particularly attractive feature of this toxin
neutralisation strategy is that, unlike antibiotic therapy, it
applies no selective pressure for evolution of resistance by
the pathogen. Blocking toxin mediated host injury by the
receptor mimic would negatively affect the capacity of the
pathogen to survive and reproduce. Furthermore, muta-
tions in a toxin sequence that prevents binding to a recep-
tor mimic would logically also prevent the toxin from
interacting with its natural target, thereby attenuating
virulence. Therefore, widespread use of such agents in a
therapeutic setting should have negligible long-term
adverse consequences. As well as treating enteric infec-
tions, 'designer probiotics' are among the most recent
conscripts in the war against AIDS, expressing HIV
receptors which compete with host cell receptors for the
virus, thus providing a natural innate barrier to HIV
attachment and infection [21].
Prophylaxis
In addition to infection control (Fig. 3), probiotics can
also be engineered to function as novel vaccine delivery
vehicles which can stimulate both innate and acquired
immunity, but lack the possibility of toxicity which exists
with more conventional vaccines that rely on live attenu-
ated pathogens [22]. Probiotic vaccine carriers adminis-
tered by the mucosal route (i.e. orally or by nasal spray)
mimic the immune response elicited by natural infection
and can lead to long lasting protection. Mucosal vaccine
delivery also offers significant technological and com-
mercial advantages over traditional formulations includ-
ing: reduced pain and the possibility of cross
contamination associated with intramuscular injection,
as well as the lack of necessity for medically trained per-
Figure 1 Scanning electron micrograph of the probiotic strain 
Lactobacillus salivarius UCC118 at a magnification of 25,000 ×. 
False colour added by Pat Casey.
Figure 2 Overview of the anti-bacterial potential of designer pro-
biotics. Bacteriocin produced by the probiotic (blue) can lyse invading 
pathogens (red) (A) while heterologously expressed receptor mimics 
on the surface of probiotic cells can antagonise pathogen adherence 
to the host (B) and neutralise toxin production (C). Imaged reproduced, 
with permission, from [18].
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sonnel to administer the vaccine - important consider-
ations for large scale vaccination protocols in less well
developed countries. Furthermore, not only do probiotics
circumvent in vivo sensitivity to gastric acidity associated
with oral application of therapeutic or prophylactic com-
pounds, they can also be produced cheaply; grown to
high levels, dried and stored for years at ambient temper-
atures.
Beyond conventional antibiotic therapies
In conclusion then, "designer probiotics" can be engi-
neered to kill pathogens, neutralise toxins, and facilitate
re-colonisation of the resident beneficial microflora while
at the same time priming both the innate and adaptive
immune system; strengthening the host against subse-
quent infection - an approach far beyond the reach of
conventional antibiotic therapies. Thus, the war against
the antibiotic resistant "super bugs" may eventually be
won by recruiting engineered "good bugs" as our allies.
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Figure 3 Mice orally infected with a luminescent bacterial patho-
gen (Listeria monocytogenes). The mouse on the left was subse-
quently fed with a probiotic (Lb. salivarius UCC118), which inhibited the 
pathogen, thus quenching the light. The mouse on the right was in-
stead given a placebo, which had no effect on infection or light pro-
duction. The image was taken by Pat Casey using the IVIS Imaging 
System 100 Series from Xenogen.
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